245 related articles for article (PubMed ID: 31315622)
1. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Ohkura Y; Ueno M; Udagawa H
World J Surg Oncol; 2019 Jul; 17(1):125. PubMed ID: 31315622
[TBL] [Abstract][Full Text] [Related]
2. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Yoshida Y; Komori K; Aoki M; Sandou M; Takagi M; Uejima E
Pharmazie; 2018 Oct; 73(10):613-616. PubMed ID: 30223928
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Cost-effectiveness of Pegfilgrastim for Preventing Febrile Neutropenia During Docetaxel, Cisplatin, and 5-Fluorouracil Therapy for Esophageal Cancer.
Kurogochi T; Matsumoto A; Nyumura Y; Tanishima Y; Nakayoshi T; Okamoto T; Yano F; Eto K
Anticancer Res; 2023 May; 43(5):2293-2298. PubMed ID: 37097646
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients.
Yoshimoto T; Oshima T; Fukada T; Imamura N; Nakanishi T; Ebisutani N; Morishita D; Mieno M; Nakai K; Sei H; Kitayama Y; Eda H; Okugawa T; Tomita T; Fukui H; Shinzaki S
Int J Clin Oncol; 2024 Feb; 29(2):142-148. PubMed ID: 38063978
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer.
Ichimura T; Nomura H; Shimizu H; Machida Y; Suzuki K
Pharmazie; 2021 Sep; 76(9):450-454. PubMed ID: 34481537
[No Abstract] [Full Text] [Related]
7. [Impact of Primary Prophylaxis with Pegfilgrastim on Clinical Outcomes in Patients with Advanced Esophageal Cancer Receiving Chemotherapy with Docetaxel, Cisplatin ,and 5-FU].
Yasuda T; Ishikawa T; Ohta T; Yoshida J; Doi T; Dohi O; Okayama T; Yoshida N; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Naito Y; Itoh Y
Gan To Kagaku Ryoho; 2018 Dec; 45(12):1733-1736. PubMed ID: 30587730
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.
Maeda O; Furune S; Kanda M; Miyata K; Shimizu D; Sugita S; Nishida K; Ando M; Kodera Y; Ando Y
Cancer Med; 2024 Jan; 13(2):e6974. PubMed ID: 38348961
[TBL] [Abstract][Full Text] [Related]
9. [Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].
Gunjigake K; Okamoto K; Gabata R; Yamaguchi T; Ninomiya I; Fushida S; Ohta T
Gan To Kagaku Ryoho; 2019 Jan; 46(1):61-63. PubMed ID: 30765644
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
Okamoto K; Ninomiya I; Saito H; Shimada M; Yamaguchi T; Terai S; Moriyama H; Kinoshita J; Nakamura K; Inaki N
Anticancer Res; 2022 May; 42(5):2783-2790. PubMed ID: 35489772
[TBL] [Abstract][Full Text] [Related]
12. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Hashimoto M; Shirakawa Y; Maeda N; Tanabe S; Noma K; Sakurama K; Katsui K; Nishizaki M; Fujiwara T
Esophagus; 2020 Apr; 17(2):127-134. PubMed ID: 31897761
[TBL] [Abstract][Full Text] [Related]
13. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
[TBL] [Abstract][Full Text] [Related]
14. Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
Inagaki T; Sato M; Kin M; Otsuka K; Murakami M; Kogo M
Anticancer Res; 2022 Dec; 42(12):6071-6081. PubMed ID: 36456156
[TBL] [Abstract][Full Text] [Related]
15. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
[TBL] [Abstract][Full Text] [Related]
17. Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy.
Nara K; Yamamoto T; Sato Y; Yagi K; Kawasaki K; Toriumi T; Takada T; Seto Y; Suzuki H
Support Care Cancer; 2023 Feb; 31(2):150. PubMed ID: 36737558
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.
Akiyama Y; Sasaki A; Endo F; Nikai H; Amano S; Umemura A; Baba S; Chiba T; Kimura T; Takahara T; Nitta H; Otsuka K; Mizuno M; Kimura Y; Koeda K; Iwaya T
World J Surg Oncol; 2018 Jul; 16(1):122. PubMed ID: 29966526
[TBL] [Abstract][Full Text] [Related]
19. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
Cobb PW; Moon YW; Mezei K; Láng I; Bhat G; Chawla S; Hasal SJ; Schwartzberg LS
Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
